Mannan-binding lectin (MBL) deficiency is determined by MBL gene polymorphisms and is associated with an increased infection risk. To clarify the role of MBL in Allo-SCT, 131 recipients-donors were analysed. MBL genotypes were determined by PCR and heteroduplex analyses, MBL serum levels by ELISA, and MBL oligomers by western blotting. MBL levels o400 ng/ml were associated with increased susceptibility to fungal pneumonia (7/12 vs 35/111; P ¼ 0.04, adjusted P ¼ 0.002), HSV/VZV (7/12 vs 26/111; P ¼ 0.03), CMV reactivation and acute GVHD. Donor genotypes had no influence. Pre-SCT MBL levels corresponded to recipients' genotypes (Po0.001), changed significantly post-SCT, but were not influenced by donors' genotypes. MBL oligomer profiles were similar pre-/post-SCT. Cultured CD34 þ cells were found not to synthesise MBL. In conclusion, low MBL levels pre-transplant predisposed patients to sepsis, fungal and viral infection. Donors' MBL genotypes did not influence infection rates. Prospective studies should clarify the importance of MBL as a prelude for MBL replacement after SCT.
Introduction
Mannan-binding lectin (MBL) is a component of the innate immune system. The carbohydrate recognition domain of the MBL protein binds to polysaccharides of microorganisms and activates the C 0 system in an Ab-independent manner. 1 Mutations in the structural and regulatory sequences of the MBL gene lead to much inter-individual variation.
2 MBL variants because of single nucleotide polymorphisms in exon 1-B (G54D), C (G57E) and D (R52C) 1, 3 -are found in B30% of the general population. Several studies have shown increased infection rates in patients with low MBL levels 4, 5 and also in neutropenia after chemotherapy. 6, 7 Recently, MBL variants were associated with an increased risk of infections in myeloablative, TBI-conditioned transplantation. 8 Conversely, patients with wild-type (WT) genotypes have a reduced risk of sepsis during Auto-SCT. 9 Limited studies show an influence of both recipients and donor genotypes [10] [11] [12] on the infection risk in this setting. In solid organ recipients, MBL deficiency is associated with increased CMV reactivation. 11 MBL may also influence the development of GVHD and graft rejection in solid organ recipients. 13 We analysed 131 stem cell recipients to evaluate the influence of MBL on TRM, infection, and acute GVHD (aGVHD) in the Allo-SCT setting.
Patients and methods

Patients
From January 2001 to October 2003 a total of 131 patients, who received Allo-SCT from related-unrelated donors at the University of Hamburg, Germany, were enrolled in a combined pro-/retrospective study after approval of the ethics committee and patients' informed consent.
MBL genotype and protein analyses Blood for MBL pheno-and genotypes was collected pretransplant, on days 0-45 and days þ 46-75 post transplant. MBL serum levels were determined by ELISA (Antibody Shop, Copenhagen, Denmark). DNA was isolated from whole-blood samples (QIAamp DNA, blood mini kit, Qiagen, Hilden, Germany).
The MBL variants in exon 1 B, C and D (codons 54, 57 and 52) were determined by PCR and heteroduplex analyses using PAGE.
14 Patients homozygous for wild-type alleles were denoted A/A, homozygous for variant alleles O/O and heterozygous A/O. Promoter polymorphisms of MBL were determined similarly. 15 The structural MBL-2 mutations B, C and D are in linkage disequilibrium with the promoter region polymorphism X/Y; therefore only Y associates with variant alleles. Western blot analyses of MBL protein pre-and posttransplant were performed using SDS-PAGE gel (Hybond C extra, Amersham Biosciences, Little Chalfont, Buckhinghamshire, UK) and immunoblotting as described earlier. 16 To investigate whether MBL is synthesised by CD34 þ cells, mononuclear cells were obtained from three BM samples (donors with MBL wild type) and CD34 þ cells were separated and cultured as described earlier. 17 MBL concentrations in cultures were analysed on day 14 using the ELISA.
Infection, GVHD and TRM Patients were monitored during the study period (days 0 to þ 75) for the frequency of infections, GVHD and TRM. Blood cultures, C-reactive protein and imaging were performed when infection was suspected. Definite sepsis was diagnosed in the case of positive blood cultures and clinical and/or laboratory sepsis evidence. Clinical sepsis was diagnosed in the absence of a positive blood culture. Diagnosis of sepsis was retrospectively made by two blinded clinicians. Viral reactivation, GVHD and TRM were also recorded. Fungal pneumonia was defined as presumed, possible or definitive. 18 
Statistical analysis
Results
Patients' and donors' characteristics
Characteristics of donors and recipients are summarised in Table 1 . Analysis of MBL genotypes MBL-2 genotypes were successfully determined in 130 patients and donors. Donors' and recipients' genotypes were similarly distributed and corresponded to earlier data (Table 2) .
4,9,19
Infection Fifty-six patients suffered from one clinical septic episode or more. Definite (blood culture positive, most frequently with Gram-positive organisms) sepsis was observed in 50 patients (n ¼ 72). There were 18 Gram-negative septic episodes and seven patients developed fungal sepsis. The first episode occurred between days 0 and þ 252 post transplant (median 52). More than 50% of patients suffered from pneumonia, a third from CMV reactivation and a quarter from VZV/ HSV reactivation (Table 1) .
MBL genotype and infection
There was no significant association between MBL genotypes and sepsis. Thirty-seven of 87 MBL wild-type patients developed bacterial sepsis compared with 13 of 43 patients with variant alleles (P ¼ 0.32). No association was observed between recipients' MBL genotypes and pneumonia (P ¼ 0.26) or CMV reactivation (P ¼ 0.96). VZV/ HSV reactivation was higher in patients with variant alleles (15/43 compared with 18/87 patients with MBL wild type, P ¼ 0.08). Donor MBL genotype was not associated with any above parameter.
MBL genotypes of recipients and donors did not influence the severity of aGVHD (P ¼ 0.76 and 0.28) or TRM (P ¼ 0.44 and 0.26).
MBL phenotype analysis
Pre-SCT MBL levels (available from 123 patients) were significantly related to MBL-2 genotypes (Po0.001) (Figure 1 ). In 29 of 87 A/A genotype patients, in whom MBL levels were available pre-SCT, on days 0-45 and þ 46-75 (Figure 2a) , MBL levels increased significantly from a mean of 3580 ng/ml pre-transplant to 5767 ng/ml by day þ 45 (Po0.001). Levels declined over the next 30 days to a mean of 4136 ng/ml (P ¼ 0.15). In a robustness analysis excluding two patients of this group because of extreme Table 2 Frequency of MBL exon-1 and X/Y promoter polymorphisms
MBL genotype
Recipient n (%) Donor n (%) values, results were similar (3000-4343 ng/ml by day þ 45; P ¼ 0.02 and 3758 ng/ml by day 75; P ¼ 0.20).
In 19 of 43 A/O and O/O patients, samples were available for all three time points. MBL levels increased from a mean of 1021 ng/ml pre-transplant to 1476 ng/ml by day þ 45 (P ¼ 0.32) and fell to a mean of 594 ng/ml by days 46-75 (P ¼ 0.21, Figure 2a) . If YA/YD individuals (whose levels are frequently in the same range as in A/A) were included in the wild-type group, the pattern remained similar (Figure 2b) .
To investigate whether MBL levels were influenced by donor-derived cells, levels were measured in 14 variant patients (A/O or O/O) with wild-type donors. Levels did not change significantly pre-to post-transplant (P ¼ 0.26) and did not alter in wild-type recipients and variant donors (n ¼ 11, P ¼ 0.92).
To explore MBL expression after SCT, western blot analysis was performed from a YA/YD recipient who received SCT from a XA/XA donor. MBL concentrations pre-transplant were 843 and 993 ng/ml post transplant. MBL protein profiles pre-and post-SCT were similar, and did not increase in high-order oligomers as seen in WT individuals (Figure 3) . Finally, MBL was not detectable from CD34 þ cells cultured from three donor marrows with wild-type MBL genotype.
MBL phenotype and infection
Sepsis rates were not significantly associated with MBL levels o400 ng/ml (P ¼ 0.57), but MBL levels in the first or last quartile (low and high MBL levels, 790XMBL43418 ng/ml) showed an increased risk of culture-proven sepsis (P ¼ 0.05) and a trend towards clinical sepsis (P ¼ 0.07) and fungal pneumonia (P ¼ 0.06) when compared with the second or the third quartiles (normal MBL levels, 790oMBLp3418 ng/ml). Twelve patients had levels of o400 ng/ml (lowest 10%) and suffered significantly more from fungal pneumonia (7/12 vs 35/111; P ¼ 0.04), HSV/VZV infection/reactivation (7/12 vs 26/111; P ¼ 0.03), and also CMV infection/reactivation was higher (6/12; 50% vs 36/111; 32%; NS, Figures 4a-c) . When multivariable analysis was performed, the risk of fungal pneumonia was significantly higher in male patients (HR ¼ 2.9, P ¼ 0.008) and in patients with serum MBL levels p400 ng/ml (HR ¼ 4.1, P ¼ 0.002). MBL was the only factor associated with risk of sepsis, HSV/VZV and CMV infection/reactivation.
MBL phenotype and risks of GVHD and TRM
There was no significant association between MBL levels and TRM or aGVHD. However, 7 of 12 patients with MBL levels o400 ng/ml suffered from aGVHD compared with 37 of 111 with MBL levels X400 ng/ml (58 vs 33%, Figure 4d) , half of the patients with MBL levels o400 ng/ ml suffered from TRM compared with 31 of 111 patients (50 vs 28%).
Discussion
Infections still contribute to TRM in recipients of Allo-SCT. Earlier studies have suggested an influence of MBL status on infection in neutropenic patients. 6, 7 We analysed 131 stem cell recipients to clarify the role of donors' and recipients' MBL genotypes and MBL serum levels on infectious and transplant-related complications.
MBL genotype did not significantly influence infections, GVHD or TRM in this study, whereas earlier studies found an association between MBL genotype and transplantrelated complications. 8, 10 However, we found an association between low MBL levels and fungal pneumonia, HSV/ VZV infection and observed a relationship between sepsis and low and high MBL levels. Thus, MBL levels may be more important than genotypes in this setting. Mannose-binding lectin serum levels increased significantly after SCT before returning to pre-transplant levels by day þ 75. Overall, the mean MBL levels pre-transplant were elevated to twice those in healthy populations, which may reflect the pro-inflammatory state of patients undergoing SCT. 1 We investigated the hypothesis that donor genotypes influence MBL levels. 10, 15 Levels did not significantly change in variant patients (A/O or O/O) with WT donors. In addition, MBL levels did not alter in WT recipients who received SCT from variant donors, and donor genotypes did not influence the risk of transplant-related complications. We also failed to detect MBL in cultured CD34 þ stem cells or a change to the oligomeric MBL profile in a patient with a heterozygous MBL genotype who received a wild-type donor SCT. Our results therefore support the study of Kilpatrick et al. 20 in which there was no effect of donor genotype on circulating MBL levels in two patients receiving SCT. In contrast, after liver transplantation, the genotype of the donor confers the subsequent MBL phenotype. Donations of livers (the main MBL source) from variant donors to wild-type recipients resulted in rapidly decreasing MBL serum levels. 21 This is in line with earlier studies 22 in which donors' genotypes did not influence transplant-related complications. Therefore, it is unclear how to explain the findings of Mullighan et al. and Granell et al. 10, 12 that transplantation outcome depended on MBL genotypes of both recipients and donors.
The observations from this study that the only clinically significant associations were related to MBL levels indicate that phenotype may be more important than genotype in predicting susceptibility to infection. Fifty-eight percent of patients with low MBL levels developed presumed fungal pneumonia and HSV/VZV reactivation, compared with 31 and 23% in patients with pre-SCT levels 4400 ng/ml. Two patients with wild-type genotype and MBL levels of o400 ng/ml developed sepsis and fungal pneumonia. The low levels might be related to pre-transplant clinical status. Surprisingly, two homozygous O/O patients had MBL serum levels of 4400 ng/ml although there is normally a strong correlation between MBL genotype and phenotype. One hypothesis might be repeated erythrocyte transfusions from donors with higher MBL but this alone is unlikely to fully explain these findings. The MBL levels of these two patients decreased post transplant.
Mannose-binding lectin deficiency has emerged as a risk factor for mycosis probably because of the presence of MBL ligands such as mannan on various fungi. 23 We also observed a relationship with HSV/VZV reactivation.
There is considerable debate about the definition of low MBL levels. Earlier studies indicated that susceptibility to infection might vary at different MBL levels depending on clinical circumstances and patient age. The use of different assays might also contribute to MBL level variability. 24 Earlier we found that MBL levels of o400 ng/ml did not activate complement after incubation with bacteria and Figure 4 Association of very low MBL serum levels (o400 ng/ml) with infection and acute GVHD.
failed to enhance MBL-mediated opsonophagocytosis. 25 Levels p400 ng/ml correlated highly with YO/YO, XA/YB or XA/YC genotypes in 500 healthy children (own unpublished observations). Our data are consistent with earlier reports showing an association between low MBL levels and increased infection rates in haematological patients with neutropenia 6, 7 and of a protective role of WT MBL genotype during Auto-SCT. 9 In addition, we observed an increased rate of sepsis, not only in patients with low MBL levels but also in patients with very high levels. Schlapbach et al. 7 saw similar results in a study of 94 paediatric cancer patients with treatment-associated neutropenia.
Why high MBL levels should predispose patients to sepsis remains unclear. MBL might influence the host inflammatory response to invading microorganisms. In ex vivo experiments, MBL levels had a dose-dependent effect on the inflammatory response to Neisseria meningitides, 26 and MBL influenced anti-inflammatory cytokines. 27 The balance between pro-and anti-inflammatory responses has been shown to influence the susceptibility to sepsis; 28 therefore high and low MBL levels might increase sepsis rates. High MBL levels may also merely reflect the inflammatory response to infection.
In conclusion, low MBL levels predispose patients undergoing SCT to sepsis, fungal pneumonia and HSV/ VZV infection. Larger prospective studies should fully evaluate the effect of MBL status after SCT and the potential role of MBL replacement therapy to prevent infection in this clinical setting.
